Neoadjuvant Endocrine Therapy for Operable Breast Cancer: A Retrospective Analysis of Real-World Use
Author:
Affiliation:
1. Department of Breast Surgery and Oncology, Nippon Medical School
2. Ninomiya Hospital, Saitama
3. Department of Breast Surgery and Oncology, Tokyo Kyosai Hospital
4. Department of Diagnostic Pathology, Nippon Medical School Hospital
Publisher
Medical Association of Nippon Medical School
Subject
General Medicine
Link
https://www.jstage.jst.go.jp/article/jnms/88/5/88_JNMS.2021_88-603/_pdf
Reference40 articles.
1. 1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-85. doi: 10.1200/JCO.1998.16.8.2672. PubMed PMID: 9704717.
2. 2. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol. 1999;10(1):47-52. doi: 10.1023/a:1008337009350. PubMed PMID: 10076721.
3. 3. Burstein HJ, Curigliano G, Loibl S, et al; Members of the St Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541-57. doi: 10.1093/annonc/mdz235. PubMed PMID: 31373601.
4. 4. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244-54. doi: 10.1002/cncr.22789. PubMed PMID: 17538978.
5. 5. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1(1):CD004272. doi: 10.1002/14651858.CD004272.pub2. PubMed PMID: 16437480.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis;European Journal of Cancer;2023-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3